<DOC>
	<DOCNO>NCT00211939</DOCNO>
	<brief_summary>The purpose study evaluate effect two phosphate binder , PhosLo sevelamer , heart calcification dialysis patient . The study use non-invasive technique , electron beam compute tomography ( CT ) scanning , measure calcium coronary artery , aortic valve , mitral valve .</brief_summary>
	<brief_title>CARE-2 ( Calcium Acetate PhosLo®/SevelamerRenagel® Evaluation Study 2 ) Heart Calcification Dialysis Patients</brief_title>
	<detailed_description>Cardiovascular disease major cause death disability patient end-stage renal disease hemodialysis . It hypothesize ingestion calcium-based phosphate binder result net positive calcium balance vascular calcium deposition . Chertow et al . test role ingested calcium progression cardiovascular calcification Treat-To-Goal study ( Kidney International 62:245 , 2002 ) . They report patient treat calcium-based phosphate binder demonstrate progressive cardiovascular calcification , patient treat calcium-free binder , sevelamer , show stabilization improvement calcification score . However , protocol prohibit intake supplemental oral calcium sevelamer group , confound ability accurately test calcium hypothesis . Moreover , due cholesterol sequester activity sevelamer , low-density lipoprotein ( LDL ) cholesterol low among sevelamer-treated patient calcium treat patient , result major imbalance cardiovascular risk factor . Lowering LDL level reduces progression CVC therefore confound interpretation study . Subsequently , report lay press patient randomized sevelamer calcium-based binder Dialysis Clinical Outcomes Revisited ( DCOR ) study fail show difference mortality major secondary endpoint ( Suki et al. , To present American Society Nephrology November 2005 ) . To circumvent limitation , CARE-2 study test hypothesis LDL level lower similar level calcium acetate sevelamer-treated patient , difference progression cardiac calcification . CARE-2 randomize patient elevate LDL calcium acetate sevelamer . Atorvastatin add achieve LDL &lt; 70 mg/dL treatment group . The primary endpoint change cardiac calcification score , determine electron beam scan 1 year . Secondary endpoint include ability calcium acetate sevelamer control phosphorus meet NKF-K/DOQI guideline .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>Eligible subject male female patient endstage renal disease maintenance hemodialysis le 5 year , elevate LDL cholesterol Currently treat oral phosphate binder Coronary artery calcium score 30 5000 Agatston unit measure electron beam CT scan Written informed consent Negative serum pregnancy test appropriate Expect comply protocol procedure schedule Unstable angina pectoris Severe congestive heart failure Severe obstructive pulmonary disease require supplemental oxygen Severe liver dysfunction Severe malnutrition Severe hyperparathyroidism Known HIV Active malignancy subject receive chemotherapy radiation Planned renal transplant within next year Clinical evidence calciphylaxis recent history hypercalcemia History obstruct bowel Hypersensitivity component study medication History swallow disorder Weight &gt; 300 pound Any condition make patient participation patient 's best interest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>PhosLo ( Calcium acetate )</keyword>
	<keyword>Renagel ( sevelamer , polyallylamine HCL )</keyword>
	<keyword>kidney dialysis</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>Kidney failure</keyword>
</DOC>